These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17709155)

  • 1. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.
    Borroni B; Gardoni F; Parnetti L; Magno L; Malinverno M; Saggese E; Calabresi P; Spillantini MG; Padovani A; Di Luca M
    Neurobiol Aging; 2009 Jan; 30(1):34-40. PubMed ID: 17709155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
    Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
    Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy.
    Borroni B; Malinverno M; Gardoni F; Grassi M; Parnetti L; Agosti C; Alberici A; Premi E; Bonuccelli U; Gasparotti R; Calabresi P; Di Luca M; Padovani A
    J Alzheimers Dis; 2010; 22(1):195-203. PubMed ID: 20847421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker].
    Urakami K; Nakashima K
    Rinsho Shinkeigaku; 2002 Nov; 42(11):1162-4. PubMed ID: 12784694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
    Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
    J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of progressive supranuclear palsy: can measurement of tau forms help?
    Kuiperij HB; Verbeek MM
    Neurobiol Aging; 2012 Jan; 33(1):204.e17-8. PubMed ID: 20947213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
    Jellinger KA
    Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
    J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP.
    Josephs KA; Petersen RC; Knopman DS; Boeve BF; Whitwell JL; Duffy JR; Parisi JE; Dickson DW
    Neurology; 2006 Jan; 66(1):41-8. PubMed ID: 16401843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains.
    Ingelsson M; Ramasamy K; Russ C; Freeman SH; Orne J; Raju S; Matsui T; Growdon JH; Frosch MP; Ghetti B; Brown RH; Irizarry MC; Hyman BT
    Acta Neuropathol; 2007 Nov; 114(5):471-9. PubMed ID: 17721707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.
    Arai H; Morikawa Y; Higuchi M; Matsui T; Clark CM; Miura M; Machida N; Lee VM; Trojanowski JQ; Sasaki H
    Biochem Biophys Res Commun; 1997 Jul; 236(2):262-4. PubMed ID: 9240421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.
    Yasui K; Inoue Y; Kanbayashi T; Nomura T; Kusumi M; Nakashima K
    J Neurol Sci; 2006 Dec; 250(1-2):120-3. PubMed ID: 17005202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Corticobasal degeneration and atypical progressive supranuclear palsy: their symptomatology, laboratory examination and differential diagnosis].
    Morimatsu M; Negoro K; Mori H
    Rinsho Shinkeigaku; 2004 Nov; 44(11):982-5. PubMed ID: 15651349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
    Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R
    Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome.
    Aerts MB; Esselink RA; Bloem BR; Verbeek MM
    Mov Disord; 2011 Jan; 26(1):169-73. PubMed ID: 20836136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.